Drug glossary Drug

AMG-410

A drug being studied in colorectal cancer trials. It appears in 1 clinical trial.

See its trials
United States No data
European Union Investigational
Spain Not available

What it is

AMG 410 is an experimental drug being studied by Amgen. It is currently in Phase 1 clinical trials for advanced or metastatic solid tumors, including colorectal cancer, specifically in patients whose tumors have KRAS alterations (changes). These trials are designed to determine the safe dosage, how the drug is processed by the body (pharmacokinetics), its effects on the body (pharmacodynamics), and whether it shows early signs of fighting the cancer. AMG 410 is taken orally (by mouth). The trials may involve giving AMG 410 alone or in combination with other cancer drugs like panitumumab or pembrolizumab. The goal is to find the best dose and understand how AMG 410 works in patients with KRAS-altered tumors.

How it works

AMG 410 is being investigated as a potential treatment for cancers with KRAS alterations. KRAS is a gene that can become altered (mutated or amplified) in some cancers, including colorectal cancer, and these alterations can drive tumor growth. AMG 410 is designed to target the effects of these KRAS alterations. The specific molecular target or mechanism of action is being characterized in these early clinical trials. It is being studied both as a single treatment and in combination with other therapies.

Common side effects

As AMG 410 is an investigational drug in Phase 1 trialsIts side effects are still being evaluated. The primary focus of Phase 1 trials is to assess safety and determine the maximum tolerated dose. Information about specific common or serious side effects is not yet fully established and will be gathered as the trials progress. Participants in the trials will be closely monitored for any adverse events

Not all are listed, and everyone experiences them differently. If you notice any, tell your care team.